| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 63 | 2024 | 760 | 11.050 |
Why?
|
| Primary Health Care | 36 | 2024 | 848 | 4.940 |
Why?
|
| Diabetes Mellitus | 26 | 2019 | 530 | 4.600 |
Why?
|
| Hypoglycemic Agents | 20 | 2019 | 288 | 3.500 |
Why?
|
| Humans | 179 | 2024 | 18430 | 3.410 |
Why?
|
| Middle Aged | 108 | 2024 | 8284 | 2.940 |
Why?
|
| Aged | 85 | 2024 | 6417 | 2.870 |
Why?
|
| Male | 119 | 2024 | 10440 | 2.800 |
Why?
|
| Female | 122 | 2024 | 13136 | 2.510 |
Why?
|
| Internet | 14 | 2019 | 243 | 2.470 |
Why?
|
| Glycated Hemoglobin A | 23 | 2022 | 233 | 2.350 |
Why?
|
| Physician-Patient Relations | 14 | 2019 | 197 | 2.350 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2024 | 407 | 2.170 |
Why?
|
| Adult | 71 | 2024 | 7910 | 2.090 |
Why?
|
| Chronic Disease | 7 | 2024 | 468 | 2.000 |
Why?
|
| Delivery of Health Care | 8 | 2023 | 444 | 1.920 |
Why?
|
| Patient-Centered Care | 6 | 2019 | 228 | 1.890 |
Why?
|
| Communication | 10 | 2019 | 202 | 1.750 |
Why?
|
| Self Report | 5 | 2024 | 256 | 1.610 |
Why?
|
| Hypertension | 15 | 2023 | 524 | 1.570 |
Why?
|
| Patient Compliance | 14 | 2009 | 318 | 1.550 |
Why?
|
| Self-Management | 3 | 2024 | 30 | 1.530 |
Why?
|
| Electronic Health Records | 11 | 2024 | 747 | 1.530 |
Why?
|
| Blood Glucose | 14 | 2022 | 346 | 1.500 |
Why?
|
| Self Care | 8 | 2012 | 175 | 1.460 |
Why?
|
| Physicians, Primary Care | 6 | 2016 | 74 | 1.460 |
Why?
|
| Medical Records Systems, Computerized | 13 | 2009 | 95 | 1.430 |
Why?
|
| Patient Portals | 3 | 2019 | 25 | 1.420 |
Why?
|
| Blood Glucose Self-Monitoring | 5 | 2017 | 43 | 1.380 |
Why?
|
| Insulin | 9 | 2019 | 208 | 1.380 |
Why?
|
| Cohort Studies | 30 | 2022 | 2672 | 1.360 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 630 | 1.240 |
Why?
|
| Office Visits | 3 | 2019 | 86 | 1.200 |
Why?
|
| Depression | 7 | 2019 | 518 | 1.180 |
Why?
|
| Evidence-Based Medicine | 7 | 2015 | 195 | 1.150 |
Why?
|
| Reminder Systems | 6 | 2014 | 94 | 1.150 |
Why?
|
| United States | 26 | 2024 | 4164 | 1.110 |
Why?
|
| Attitude of Health Personnel | 13 | 2016 | 226 | 1.100 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 2003 | 1.060 |
Why?
|
| Risk Factors | 25 | 2024 | 3449 | 1.050 |
Why?
|
| Health Behavior | 9 | 2012 | 374 | 1.040 |
Why?
|
| Patient Care Management | 5 | 2020 | 32 | 1.030 |
Why?
|
| Disease Management | 8 | 2019 | 143 | 1.010 |
Why?
|
| Motivation | 7 | 2022 | 137 | 1.000 |
Why?
|
| Genetic Testing | 5 | 2012 | 89 | 0.980 |
Why?
|
| Multiple Chronic Conditions | 2 | 2024 | 25 | 0.960 |
Why?
|
| California | 11 | 2024 | 2365 | 0.950 |
Why?
|
| Residence Characteristics | 2 | 2022 | 256 | 0.940 |
Why?
|
| Medical Informatics | 4 | 2015 | 45 | 0.940 |
Why?
|
| Genetic Counseling | 3 | 2012 | 35 | 0.930 |
Why?
|
| Hospitalization | 9 | 2024 | 847 | 0.930 |
Why?
|
| Monitoring, Physiologic | 3 | 2015 | 41 | 0.920 |
Why?
|
| Massachusetts | 18 | 2015 | 99 | 0.910 |
Why?
|
| Information Systems | 5 | 2012 | 23 | 0.880 |
Why?
|
| Decision Making | 6 | 2018 | 204 | 0.870 |
Why?
|
| Risk Assessment | 11 | 2024 | 1143 | 0.840 |
Why?
|
| Caregivers | 4 | 2024 | 126 | 0.820 |
Why?
|
| Patient Education as Topic | 6 | 2019 | 214 | 0.780 |
Why?
|
| Hispanic Americans | 4 | 2017 | 428 | 0.780 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2012 | 254 | 0.780 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2024 | 567 | 0.780 |
Why?
|
| Qualitative Research | 7 | 2024 | 272 | 0.780 |
Why?
|
| Patient Participation | 8 | 2019 | 144 | 0.760 |
Why?
|
| Medicaid | 2 | 2022 | 211 | 0.760 |
Why?
|
| Prevalence | 12 | 2020 | 911 | 0.760 |
Why?
|
| Ambulatory Care | 7 | 2019 | 266 | 0.740 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 90 | 0.730 |
Why?
|
| Physicians, Family | 7 | 2009 | 47 | 0.720 |
Why?
|
| Burnout, Professional | 1 | 2020 | 16 | 0.700 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 13 | 0.700 |
Why?
|
| Focus Groups | 5 | 2022 | 154 | 0.700 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.690 |
Why?
|
| Life Style | 5 | 2013 | 342 | 0.690 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 724 | 0.680 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 53 | 0.680 |
Why?
|
| Retroviridae Infections | 2 | 2017 | 2 | 0.680 |
Why?
|
| Early Detection of Cancer | 6 | 2015 | 526 | 0.670 |
Why?
|
| Health Priorities | 2 | 2016 | 28 | 0.670 |
Why?
|
| Genetic Variation | 2 | 2010 | 87 | 0.670 |
Why?
|
| Patient Preference | 1 | 2019 | 45 | 0.650 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2016 | 392 | 0.650 |
Why?
|
| Consumer Health Information | 2 | 2009 | 14 | 0.640 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2014 | 124 | 0.640 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 19 | 0.640 |
Why?
|
| Blood Pressure | 6 | 2012 | 310 | 0.640 |
Why?
|
| Young Adult | 11 | 2022 | 2518 | 0.620 |
Why?
|
| Macaca nemestrina | 2 | 2017 | 2 | 0.620 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 1389 | 0.610 |
Why?
|
| Community Health Workers | 2 | 2015 | 15 | 0.600 |
Why?
|
| Software | 5 | 2009 | 21 | 0.600 |
Why?
|
| Tumor Virus Infections | 1 | 2017 | 1 | 0.600 |
Why?
|
| Retroviruses, Simian | 1 | 2017 | 1 | 0.600 |
Why?
|
| Endogenous Retroviruses | 1 | 2017 | 1 | 0.600 |
Why?
|
| Genome, Viral | 1 | 2017 | 4 | 0.600 |
Why?
|
| Antihypertensive Agents | 3 | 2012 | 172 | 0.590 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2023 | 182 | 0.590 |
Why?
|
| Multivariate Analysis | 8 | 2015 | 598 | 0.590 |
Why?
|
| Cross-Sectional Studies | 13 | 2024 | 1360 | 0.590 |
Why?
|
| Time Factors | 10 | 2019 | 1136 | 0.580 |
Why?
|
| Drug Prescriptions | 4 | 2015 | 157 | 0.580 |
Why?
|
| Cholesterol, HDL | 2 | 2007 | 80 | 0.550 |
Why?
|
| Metabolic Syndrome | 3 | 2009 | 80 | 0.550 |
Why?
|
| Health Services Accessibility | 6 | 2022 | 320 | 0.550 |
Why?
|
| Hypercholesterolemia | 3 | 2006 | 33 | 0.540 |
Why?
|
| Motor Activity | 2 | 2015 | 215 | 0.540 |
Why?
|
| Asthma | 1 | 2019 | 390 | 0.530 |
Why?
|
| Clinical Competence | 2 | 2015 | 108 | 0.530 |
Why?
|
| Clinical Protocols | 2 | 2016 | 45 | 0.530 |
Why?
|
| Health Literacy | 2 | 2016 | 40 | 0.520 |
Why?
|
| Health Status | 5 | 2012 | 328 | 0.520 |
Why?
|
| Patient Readmission | 2 | 2013 | 162 | 0.520 |
Why?
|
| Heart Failure | 2 | 2019 | 398 | 0.510 |
Why?
|
| Mass Screening | 4 | 2014 | 690 | 0.510 |
Why?
|
| Metformin | 6 | 2020 | 61 | 0.510 |
Why?
|
| Research Personnel | 1 | 2015 | 30 | 0.510 |
Why?
|
| Laboratories, Hospital | 1 | 2015 | 4 | 0.500 |
Why?
|
| Severity of Illness Index | 4 | 2012 | 476 | 0.500 |
Why?
|
| Logistic Models | 8 | 2015 | 962 | 0.500 |
Why?
|
| Academic Medical Centers | 4 | 2015 | 31 | 0.500 |
Why?
|
| Outpatients | 3 | 2019 | 111 | 0.500 |
Why?
|
| Mammography | 4 | 2012 | 174 | 0.500 |
Why?
|
| Quality Improvement | 5 | 2020 | 207 | 0.490 |
Why?
|
| Statistics as Topic | 1 | 2015 | 66 | 0.490 |
Why?
|
| Health Services Research | 2 | 2015 | 264 | 0.490 |
Why?
|
| Data Accuracy | 1 | 2015 | 27 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2016 | 350 | 0.480 |
Why?
|
| Registries | 8 | 2020 | 490 | 0.470 |
Why?
|
| Patients | 3 | 2010 | 38 | 0.460 |
Why?
|
| Health Systems Plans | 1 | 2013 | 4 | 0.460 |
Why?
|
| Treatment Outcome | 11 | 2016 | 1296 | 0.460 |
Why?
|
| Vital Signs | 1 | 2013 | 14 | 0.460 |
Why?
|
| Community Networks | 2 | 2011 | 28 | 0.460 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 10 | 0.460 |
Why?
|
| Research Design | 3 | 2016 | 402 | 0.460 |
Why?
|
| Medicine | 4 | 2009 | 23 | 0.450 |
Why?
|
| Neoplasms | 3 | 2014 | 457 | 0.450 |
Why?
|
| Documentation | 3 | 2009 | 45 | 0.450 |
Why?
|
| Retrospective Studies | 17 | 2022 | 2550 | 0.440 |
Why?
|
| Physicians | 5 | 2010 | 141 | 0.440 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 211 | 0.440 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 180 | 0.430 |
Why?
|
| Age Factors | 9 | 2019 | 965 | 0.430 |
Why?
|
| Mental Health | 2 | 2012 | 168 | 0.430 |
Why?
|
| Sulfonylurea Compounds | 2 | 2010 | 28 | 0.430 |
Why?
|
| Hyperlipidemias | 6 | 2015 | 58 | 0.420 |
Why?
|
| Rheumatology | 2 | 2009 | 8 | 0.420 |
Why?
|
| Case Management | 2 | 2011 | 37 | 0.420 |
Why?
|
| Medical Informatics Applications | 2 | 2009 | 9 | 0.410 |
Why?
|
| Obesity | 3 | 2015 | 855 | 0.410 |
Why?
|
| Health Surveys | 5 | 2019 | 269 | 0.410 |
Why?
|
| Pandemics | 3 | 2024 | 292 | 0.400 |
Why?
|
| Comorbidity | 8 | 2019 | 619 | 0.400 |
Why?
|
| Access to Information | 1 | 2012 | 13 | 0.400 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 197 | 0.400 |
Why?
|
| Cause of Death | 1 | 2012 | 185 | 0.400 |
Why?
|
| Multimorbidity | 2 | 2024 | 14 | 0.400 |
Why?
|
| Emergency Service, Hospital | 4 | 2019 | 382 | 0.400 |
Why?
|
| Socioeconomic Factors | 7 | 2016 | 673 | 0.390 |
Why?
|
| Medicare | 2 | 2023 | 214 | 0.390 |
Why?
|
| Exercise | 3 | 2013 | 495 | 0.390 |
Why?
|
| Health Records, Personal | 4 | 2012 | 13 | 0.370 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 44 | 0.370 |
Why?
|
| Specialization | 3 | 2007 | 26 | 0.370 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 6 | 0.360 |
Why?
|
| Dyslipidemias | 2 | 2010 | 65 | 0.360 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 10 | 0.360 |
Why?
|
| Quality of Health Care | 5 | 2009 | 347 | 0.350 |
Why?
|
| Coronary Disease | 6 | 2009 | 185 | 0.350 |
Why?
|
| Diagnostic Equipment | 1 | 2009 | 1 | 0.350 |
Why?
|
| Inpatients | 2 | 2008 | 80 | 0.350 |
Why?
|
| Cell Phone | 1 | 2009 | 12 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2015 | 412 | 0.340 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 54 | 0.340 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 1037 | 0.340 |
Why?
|
| Rheumatic Diseases | 1 | 2009 | 2 | 0.340 |
Why?
|
| Child | 6 | 2022 | 2571 | 0.330 |
Why?
|
| Analysis of Variance | 4 | 2015 | 167 | 0.330 |
Why?
|
| Telemedicine | 3 | 2024 | 184 | 0.330 |
Why?
|
| Cluster Analysis | 3 | 2020 | 96 | 0.320 |
Why?
|
| Attitude to Health | 2 | 2009 | 177 | 0.320 |
Why?
|
| Mental Disorders | 4 | 2020 | 295 | 0.320 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2008 | 4 | 0.320 |
Why?
|
| Adolescent | 12 | 2020 | 3798 | 0.320 |
Why?
|
| Algorithms | 8 | 2015 | 241 | 0.310 |
Why?
|
| Fractures, Bone | 2 | 2019 | 91 | 0.310 |
Why?
|
| Health Care Costs | 5 | 2019 | 251 | 0.310 |
Why?
|
| Patient Access to Records | 5 | 2007 | 18 | 0.310 |
Why?
|
| Biomedical Technology | 1 | 2007 | 2 | 0.310 |
Why?
|
| Health Care Surveys | 6 | 2011 | 247 | 0.300 |
Why?
|
| Physician's Role | 2 | 2012 | 32 | 0.300 |
Why?
|
| Pharmacogenetics | 3 | 2015 | 15 | 0.300 |
Why?
|
| Boston | 6 | 2016 | 37 | 0.300 |
Why?
|
| Hypoglycemia | 2 | 2012 | 49 | 0.300 |
Why?
|
| Cholesterol, LDL | 5 | 2010 | 125 | 0.290 |
Why?
|
| Family Practice | 2 | 2007 | 53 | 0.290 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 1269 | 0.290 |
Why?
|
| Informatics | 1 | 2006 | 3 | 0.290 |
Why?
|
| Prospective Studies | 5 | 2022 | 1314 | 0.280 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 65 | 0.280 |
Why?
|
| Insurance, Health | 2 | 2006 | 217 | 0.280 |
Why?
|
| Diabetes Complications | 3 | 2020 | 119 | 0.280 |
Why?
|
| Parents | 1 | 2009 | 309 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2009 | 365 | 0.280 |
Why?
|
| Odds Ratio | 6 | 2012 | 701 | 0.280 |
Why?
|
| Housing | 2 | 2022 | 40 | 0.270 |
Why?
|
| Diet | 3 | 2009 | 371 | 0.270 |
Why?
|
| Depressive Disorder | 1 | 2008 | 231 | 0.270 |
Why?
|
| Insurance Claim Review | 2 | 2008 | 70 | 0.270 |
Why?
|
| Prediabetic State | 3 | 2016 | 53 | 0.270 |
Why?
|
| Overweight | 3 | 2013 | 276 | 0.270 |
Why?
|
| Schizophrenia | 1 | 2006 | 79 | 0.270 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 127 | 0.270 |
Why?
|
| Data Collection | 6 | 2009 | 275 | 0.270 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 133 | 0.260 |
Why?
|
| Disease Progression | 3 | 2020 | 271 | 0.250 |
Why?
|
| Polypharmacy | 1 | 2004 | 13 | 0.250 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 15 | 0.250 |
Why?
|
| Levofloxacin | 3 | 2010 | 3 | 0.240 |
Why?
|
| Ofloxacin | 3 | 2010 | 4 | 0.240 |
Why?
|
| Hepatitis C | 1 | 2005 | 65 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2019 | 93 | 0.240 |
Why?
|
| Infection Control | 1 | 2024 | 10 | 0.240 |
Why?
|
| Pilot Projects | 5 | 2013 | 237 | 0.230 |
Why?
|
| African Americans | 1 | 2007 | 490 | 0.230 |
Why?
|
| Geriatrics | 1 | 2004 | 8 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 270 | 0.230 |
Why?
|
| Social Class | 3 | 2010 | 125 | 0.230 |
Why?
|
| Cross Infection | 1 | 2024 | 28 | 0.230 |
Why?
|
| Patient Care | 4 | 2023 | 36 | 0.230 |
Why?
|
| Medical Records | 4 | 2012 | 106 | 0.230 |
Why?
|
| Research | 2 | 2018 | 73 | 0.230 |
Why?
|
| Animals | 5 | 2017 | 261 | 0.220 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 15 | 0.220 |
Why?
|
| Attitude | 1 | 2023 | 33 | 0.220 |
Why?
|
| Poverty | 1 | 2024 | 182 | 0.210 |
Why?
|
| Patient Satisfaction | 5 | 2010 | 232 | 0.210 |
Why?
|
| Length of Stay | 4 | 2013 | 183 | 0.210 |
Why?
|
| Models, Theoretical | 2 | 2015 | 76 | 0.210 |
Why?
|
| Sepsis | 1 | 2023 | 71 | 0.210 |
Why?
|
| Probability | 3 | 2010 | 86 | 0.210 |
Why?
|
| Stress, Psychological | 3 | 2008 | 147 | 0.210 |
Why?
|
| Patient Selection | 1 | 2003 | 198 | 0.200 |
Why?
|
| Models, Statistical | 1 | 2023 | 185 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 743 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 333 | 0.200 |
Why?
|
| Cholesterol | 3 | 2006 | 112 | 0.190 |
Why?
|
| Orthopedics | 1 | 2021 | 5 | 0.190 |
Why?
|
| Quality of Life | 5 | 2024 | 529 | 0.190 |
Why?
|
| User-Computer Interface | 6 | 2011 | 28 | 0.190 |
Why?
|
| Continental Population Groups | 3 | 2008 | 315 | 0.190 |
Why?
|
| Resource Allocation | 1 | 2020 | 6 | 0.190 |
Why?
|
| Health Care Rationing | 1 | 2020 | 14 | 0.190 |
Why?
|
| Disclosure | 1 | 2021 | 19 | 0.190 |
Why?
|
| Hearing Disorders | 1 | 2000 | 3 | 0.190 |
Why?
|
| Hearing Tests | 1 | 2000 | 4 | 0.190 |
Why?
|
| Deafness | 1 | 2000 | 5 | 0.180 |
Why?
|
| Community Health Centers | 3 | 2009 | 112 | 0.180 |
Why?
|
| Professional Practice | 2 | 2011 | 16 | 0.180 |
Why?
|
| Bandages | 1 | 2020 | 1 | 0.180 |
Why?
|
| Fractures, Open | 1 | 2020 | 1 | 0.180 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2020 | 1 | 0.180 |
Why?
|
| Fracture Fixation, Internal | 1 | 2020 | 3 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 17 | 0.180 |
Why?
|
| Lower Extremity | 1 | 2020 | 13 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 7 | 0.180 |
Why?
|
| HIV Infections | 4 | 2018 | 695 | 0.180 |
Why?
|
| Upper Extremity | 1 | 2019 | 6 | 0.180 |
Why?
|
| Telephone | 2 | 2023 | 179 | 0.180 |
Why?
|
| Age of Onset | 1 | 2020 | 82 | 0.180 |
Why?
|
| Mortality | 1 | 2020 | 123 | 0.180 |
Why?
|
| Kidney | 1 | 2020 | 54 | 0.170 |
Why?
|
| Community-Acquired Infections | 3 | 2010 | 24 | 0.170 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 5 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 17 | 0.170 |
Why?
|
| Efficiency, Organizational | 3 | 2008 | 36 | 0.170 |
Why?
|
| Confidence Intervals | 2 | 2010 | 253 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2012 | 4 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 157 | 0.170 |
Why?
|
| Psychology | 1 | 2019 | 17 | 0.170 |
Why?
|
| Aza Compounds | 2 | 2010 | 2 | 0.170 |
Why?
|
| Quinolines | 2 | 2010 | 2 | 0.170 |
Why?
|
| Body Mass Index | 3 | 2009 | 974 | 0.160 |
Why?
|
| Pyridones | 1 | 2018 | 8 | 0.160 |
Why?
|
| Pelvic Bones | 1 | 2018 | 5 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1173 | 0.160 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 12 | 0.160 |
Why?
|
| Alcoholism | 1 | 2023 | 350 | 0.160 |
Why?
|
| Leg Injuries | 1 | 2018 | 8 | 0.160 |
Why?
|
| Ethnic Groups | 2 | 2020 | 501 | 0.160 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2018 | 19 | 0.160 |
Why?
|
| Health Care Reform | 2 | 2015 | 33 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2008 | 56 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 4 | 2009 | 188 | 0.160 |
Why?
|
| Glipizide | 2 | 2015 | 2 | 0.160 |
Why?
|
| Pneumonia, Bacterial | 2 | 2008 | 7 | 0.160 |
Why?
|
| Sex Factors | 4 | 2015 | 661 | 0.150 |
Why?
|
| Anxiety | 1 | 2019 | 156 | 0.150 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 40 | 0.150 |
Why?
|
| Indonesia | 1 | 2017 | 1 | 0.150 |
Why?
|
| Costs and Cost Analysis | 5 | 2015 | 89 | 0.150 |
Why?
|
| Patient Handoff | 1 | 2017 | 2 | 0.150 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 12 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 154 | 0.140 |
Why?
|
| Continuity of Patient Care | 3 | 2016 | 112 | 0.140 |
Why?
|
| Managed Care Programs | 3 | 2009 | 347 | 0.140 |
Why?
|
| Checklist | 1 | 2016 | 15 | 0.140 |
Why?
|
| Medication Adherence | 3 | 2023 | 267 | 0.140 |
Why?
|
| Communication Barriers | 1 | 2017 | 32 | 0.140 |
Why?
|
| Acculturation | 1 | 2016 | 22 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 48 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 414 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 102 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 142 | 0.130 |
Why?
|
| Thiazolidinediones | 2 | 2007 | 54 | 0.130 |
Why?
|
| Urban Population | 2 | 2007 | 124 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 656 | 0.130 |
Why?
|
| Career Mobility | 1 | 2015 | 6 | 0.130 |
Why?
|
| Research Support as Topic | 1 | 2015 | 23 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2010 | 86 | 0.130 |
Why?
|
| Astrocytoma | 1 | 1995 | 1 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 25 | 0.130 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2016 | 110 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2015 | 3 | 0.130 |
Why?
|
| Medication Errors | 2 | 2012 | 7 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2015 | 94 | 0.120 |
Why?
|
| Vulnerable Populations | 2 | 2015 | 47 | 0.120 |
Why?
|
| Electronic Mail | 2 | 2006 | 53 | 0.120 |
Why?
|
| Practice Management, Medical | 1 | 2014 | 17 | 0.120 |
Why?
|
| Glucose | 1 | 2014 | 30 | 0.120 |
Why?
|
| Alleles | 2 | 2015 | 95 | 0.120 |
Why?
|
| Educational Status | 3 | 2015 | 205 | 0.120 |
Why?
|
| Health Resources | 2 | 2019 | 38 | 0.120 |
Why?
|
| Medication Systems | 2 | 2012 | 2 | 0.120 |
Why?
|
| Health Maintenance Organizations | 2 | 2007 | 479 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2015 | 13 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2010 | 95 | 0.120 |
Why?
|
| Substance-Related Disorders | 3 | 2005 | 439 | 0.120 |
Why?
|
| Wilms Tumor | 1 | 2013 | 1 | 0.120 |
Why?
|
| Phenotype | 2 | 2015 | 148 | 0.120 |
Why?
|
| Nephrectomy | 1 | 2013 | 6 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 10 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2014 | 29 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 16 | 0.110 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2013 | 1 | 0.110 |
Why?
|
| Amino Acids, Aromatic | 1 | 2013 | 1 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2013 | 48 | 0.110 |
Why?
|
| Pharmacists | 2 | 2023 | 48 | 0.110 |
Why?
|
| Dengue | 1 | 2013 | 1 | 0.110 |
Why?
|
| Reference Values | 2 | 2010 | 93 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 100 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 342 | 0.110 |
Why?
|
| Videotape Recording | 2 | 2009 | 10 | 0.110 |
Why?
|
| Health Status Disparities | 2 | 2012 | 153 | 0.110 |
Why?
|
| Occupational Health Services | 1 | 2012 | 16 | 0.110 |
Why?
|
| Workplace | 1 | 2012 | 36 | 0.100 |
Why?
|
| Prehypertension | 1 | 2012 | 22 | 0.100 |
Why?
|
| Diabetic Angiopathies | 3 | 2007 | 36 | 0.100 |
Why?
|
| Social Support | 2 | 2019 | 214 | 0.100 |
Why?
|
| Self Administration | 1 | 2012 | 12 | 0.100 |
Why?
|
| Prognosis | 2 | 2023 | 624 | 0.100 |
Why?
|
| Safety-net Providers | 1 | 2012 | 63 | 0.100 |
Why?
|
| Awareness | 1 | 2012 | 18 | 0.100 |
Why?
|
| Models, Biological | 1 | 2012 | 32 | 0.100 |
Why?
|
| Anti-Infective Agents | 2 | 2010 | 15 | 0.100 |
Why?
|
| Interview, Psychological | 1 | 2011 | 19 | 0.100 |
Why?
|
| Social Marketing | 1 | 2011 | 13 | 0.100 |
Why?
|
| Sample Size | 1 | 2011 | 30 | 0.100 |
Why?
|
| HIV-1 | 2 | 2002 | 71 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2011 | 25 | 0.100 |
Why?
|
| Glioma | 1 | 2011 | 5 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 95 | 0.090 |
Why?
|
| Weight Loss | 1 | 2013 | 321 | 0.090 |
Why?
|
| Computer Communication Networks | 1 | 2011 | 18 | 0.090 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 2010 | 1 | 0.090 |
Why?
|
| Incidence | 3 | 2013 | 1314 | 0.090 |
Why?
|
| Home Care Services | 1 | 2011 | 23 | 0.090 |
Why?
|
| Physician Incentive Plans | 1 | 2010 | 9 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2024 | 327 | 0.090 |
Why?
|
| Hospitals, General | 1 | 2010 | 4 | 0.090 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 41 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 2013 | 65 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 131 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 61 | 0.090 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2010 | 2 | 0.090 |
Why?
|
| Drug Utilization | 3 | 2008 | 134 | 0.090 |
Why?
|
| Language | 1 | 2010 | 52 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Drug Costs | 2 | 2008 | 40 | 0.090 |
Why?
|
| Insulin Resistance | 2 | 2013 | 129 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2010 | 42 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2010 | 20 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 31 | 0.090 |
Why?
|
| Body Weight | 2 | 2008 | 223 | 0.090 |
Why?
|
| New York | 2 | 2018 | 22 | 0.090 |
Why?
|
| Privacy | 1 | 2009 | 7 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2009 | 22 | 0.090 |
Why?
|
| New England | 1 | 2009 | 13 | 0.090 |
Why?
|
| Health Promotion | 2 | 2011 | 294 | 0.090 |
Why?
|
| Medical Record Linkage | 1 | 2009 | 44 | 0.090 |
Why?
|
| Teaching | 1 | 2009 | 16 | 0.090 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 1 | 0.090 |
Why?
|
| Iceland | 1 | 2009 | 2 | 0.090 |
Why?
|
| Genome, Human | 1 | 2009 | 42 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2009 | 3 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 4 | 0.080 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 10 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2009 | 10 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2011 | 180 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 23 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2010 | 162 | 0.080 |
Why?
|
| Hospital Administration | 1 | 2009 | 3 | 0.080 |
Why?
|
| Systems Theory | 1 | 2009 | 3 | 0.080 |
Why?
|
| Pneumonia | 1 | 2010 | 56 | 0.080 |
Why?
|
| United Kingdom | 2 | 2019 | 32 | 0.080 |
Why?
|
| Perception | 1 | 2009 | 59 | 0.080 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 55 | 0.080 |
Why?
|
| Environment | 1 | 2009 | 51 | 0.080 |
Why?
|
| San Francisco | 2 | 2018 | 68 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 40 | 0.080 |
Why?
|
| Warfarin | 1 | 2009 | 73 | 0.080 |
Why?
|
| Patient Discharge | 2 | 2009 | 153 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 12 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 150 | 0.080 |
Why?
|
| Papanicolaou Test | 1 | 2008 | 38 | 0.080 |
Why?
|
| Linear Models | 2 | 2009 | 243 | 0.080 |
Why?
|
| Zoonoses | 1 | 2008 | 1 | 0.080 |
Why?
|
| Simian foamy virus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2007 | 244 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2008 | 50 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2009 | 125 | 0.080 |
Why?
|
| Macrolides | 1 | 2008 | 8 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2007 | 2 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2007 | 6 | 0.080 |
Why?
|
| Macaca fascicularis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2007 | 15 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2008 | 21 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2009 | 327 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 249 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2009 | 77 | 0.070 |
Why?
|
| Information Science | 1 | 2006 | 1 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2007 | 48 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2008 | 271 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2007 | 51 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2007 | 74 | 0.070 |
Why?
|
| Triglycerides | 1 | 2006 | 87 | 0.070 |
Why?
|
| Computational Biology | 1 | 2006 | 28 | 0.070 |
Why?
|
| West Nile virus | 1 | 2006 | 1 | 0.070 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2006 | 3 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 42 | 0.070 |
Why?
|
| Chromans | 1 | 2005 | 10 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 10 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 399 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2006 | 71 | 0.070 |
Why?
|
| Medical Order Entry Systems | 1 | 2006 | 15 | 0.070 |
Why?
|
| Natural Language Processing | 1 | 2006 | 57 | 0.060 |
Why?
|
| Atenolol | 1 | 2005 | 8 | 0.060 |
Why?
|
| Lisinopril | 1 | 2005 | 5 | 0.060 |
Why?
|
| Hydrochlorothiazide | 1 | 2005 | 5 | 0.060 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2005 | 27 | 0.060 |
Why?
|
| Preventive Health Services | 1 | 2007 | 166 | 0.060 |
Why?
|
| Nursing Assessment | 1 | 2004 | 1 | 0.060 |
Why?
|
| African Continental Ancestry Group | 3 | 2014 | 166 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2019 | 41 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2005 | 77 | 0.060 |
Why?
|
| France | 1 | 2024 | 12 | 0.060 |
Why?
|
| Masks | 1 | 2024 | 5 | 0.060 |
Why?
|
| Aging | 1 | 2005 | 165 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 80 | 0.060 |
Why?
|
| Medication Therapy Management | 1 | 2023 | 6 | 0.060 |
Why?
|
| Smoking | 1 | 2006 | 494 | 0.060 |
Why?
|
| Income | 1 | 2024 | 98 | 0.060 |
Why?
|
| Social Control, Formal | 1 | 1983 | 4 | 0.060 |
Why?
|
| Nurses | 1 | 2003 | 40 | 0.060 |
Why?
|
| Biomarkers | 2 | 2015 | 308 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 38 | 0.050 |
Why?
|
| Crisis Intervention | 1 | 2023 | 16 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2011 | 226 | 0.050 |
Why?
|
| Health Education | 1 | 2003 | 115 | 0.050 |
Why?
|
| Urinary Catheterization | 1 | 2002 | 2 | 0.050 |
Why?
|
| Health Services | 2 | 2016 | 117 | 0.050 |
Why?
|
| Urinary Incontinence | 1 | 2002 | 33 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2002 | 21 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2023 | 106 | 0.050 |
Why?
|
| England | 1 | 2021 | 4 | 0.050 |
Why?
|
| State Medicine | 1 | 2021 | 6 | 0.050 |
Why?
|
| Education, Special | 1 | 2000 | 3 | 0.050 |
Why?
|
| Cost Control | 1 | 2000 | 25 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2020 | 10 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2000 | 120 | 0.040 |
Why?
|
| Program Development | 1 | 2000 | 81 | 0.040 |
Why?
|
| Social Behavior | 1 | 1999 | 24 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 59 | 0.040 |
Why?
|
| Hospital Units | 1 | 1999 | 1 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 375 | 0.040 |
Why?
|
| Chest Pain | 1 | 1999 | 14 | 0.040 |
Why?
|
| Fluoroquinolones | 2 | 2010 | 7 | 0.040 |
Why?
|
| Tape Recording | 1 | 2018 | 6 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2018 | 3 | 0.040 |
Why?
|
| Family | 1 | 2019 | 120 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2012 | 47 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 126 | 0.040 |
Why?
|
| Asia | 2 | 2008 | 15 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 133 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 56 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2000 | 872 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2016 | 32 | 0.030 |
Why?
|
| Demography | 2 | 2007 | 108 | 0.030 |
Why?
|
| Drug Monitoring | 2 | 2009 | 22 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 24 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 69 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 17 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1995 | 4 | 0.030 |
Why?
|
| Professional Competence | 1 | 1995 | 12 | 0.030 |
Why?
|
| Workload | 1 | 2015 | 30 | 0.030 |
Why?
|
| Public Health Administration | 1 | 2015 | 6 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 106 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 1478 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 48 | 0.030 |
Why?
|
| European Continental Ancestry Group | 2 | 2008 | 554 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 21 | 0.030 |
Why?
|
| Ontario | 1 | 2013 | 16 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2013 | 1 | 0.030 |
Why?
|
| American Samoa | 1 | 2013 | 1 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2013 | 20 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 269 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 27 | 0.030 |
Why?
|
| Bacillus subtilis | 1 | 1992 | 1 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1992 | 1 | 0.030 |
Why?
|
| Spores, Bacterial | 1 | 1992 | 1 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1992 | 2 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 7 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 1992 | 18 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 11 | 0.030 |
Why?
|
| Transcription Factors | 1 | 1992 | 20 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 208 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 58 | 0.030 |
Why?
|
| Urban Health | 1 | 2012 | 40 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 4 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 249 | 0.020 |
Why?
|
| Viral Load | 2 | 2002 | 135 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 73 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 261 | 0.020 |
Why?
|
| South Africa | 1 | 2010 | 17 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1245 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 20 | 0.020 |
Why?
|
| Vitamin K | 1 | 2009 | 15 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2009 | 40 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 20 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 7 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 101 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 47 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 52 | 0.020 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 2008 | 3 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 114 | 0.020 |
Why?
|
| Ape Diseases | 1 | 2008 | 2 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 17 | 0.020 |
Why?
|
| Phylogeny | 1 | 2008 | 14 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 61 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 10 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2008 | 8 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 6 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 22 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 20 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 18 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 36 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2008 | 7 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 10 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2008 | 67 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2008 | 65 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 38 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2007 | 11 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 167 | 0.020 |
Why?
|
| Diet, Diabetic | 1 | 2007 | 9 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 10 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 11 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2006 | 21 | 0.020 |
Why?
|
| Goals | 1 | 2006 | 33 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 82 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2006 | 28 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 19 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2006 | 11 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2006 | 20 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 44 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2005 | 70 | 0.020 |
Why?
|
| Commitment of Mentally Ill | 1 | 1983 | 1 | 0.010 |
Why?
|
| Criminal Psychology | 1 | 1983 | 1 | 0.010 |
Why?
|
| Hospitals, State | 1 | 1983 | 1 | 0.010 |
Why?
|
| Deinstitutionalization | 1 | 1983 | 2 | 0.010 |
Why?
|
| Hospitals, Psychiatric | 1 | 1983 | 3 | 0.010 |
Why?
|
| Sex Work | 1 | 1983 | 5 | 0.010 |
Why?
|
| Violence | 1 | 1983 | 30 | 0.010 |
Why?
|
| Aftercare | 1 | 1983 | 48 | 0.010 |
Why?
|
| Urinary Bladder Diseases | 1 | 2002 | 5 | 0.010 |
Why?
|
| Urodynamics | 1 | 2002 | 5 | 0.010 |
Why?
|
| Prisoners | 1 | 1983 | 58 | 0.010 |
Why?
|
| Electronics | 1 | 2001 | 4 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2001 | 24 | 0.010 |
Why?
|
| Critical Pathways | 1 | 1999 | 11 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1999 | 24 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 1999 | 23 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1999 | 44 | 0.010 |
Why?
|
| Diagnosis | 1 | 1995 | 5 | 0.010 |
Why?
|
| Therapeutics | 1 | 1995 | 2 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1995 | 5 | 0.010 |
Why?
|
| Specialties, Surgical | 1 | 1995 | 2 | 0.010 |
Why?
|
| Technology | 1 | 1995 | 7 | 0.010 |
Why?
|
| Problem Solving | 1 | 1995 | 11 | 0.010 |
Why?
|
| Schools, Medical | 1 | 1995 | 17 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1995 | 25 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1995 | 127 | 0.010 |
Why?
|
| Counseling | 1 | 1995 | 197 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 1 | 0.010 |
Why?
|
| Sigma Factor | 1 | 1992 | 1 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1992 | 5 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 1992 | 13 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1992 | 31 | 0.010 |
Why?
|
| Mutation | 1 | 1992 | 132 | 0.010 |
Why?
|